Marijuana Inc. (MAJI)
| Market Cap | 2.13M |
| Revenue (ttm) | -12.83K |
| Net Income (ttm) | -661.35K |
| Shares Out | 41.05M |
| EPS (ttm) | -0.02 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 36,300 |
| Average Volume | 89,505 |
| Open | 0.0520 |
| Previous Close | 0.0600 |
| Day's Range | 0.0490 - 0.0600 |
| 52-Week Range | 0.0240 - 0.3199 |
| Beta | -4.98 |
| RSI | 45.03 |
| Earnings Date | Jun 18, 2026 |
About Marijuana
Marijuana Inc. distributes cannabis products in the United States. The company was formerly known as GRN Holding Corporation and changed its name to Marijuana Inc. in October 2024. Marijuana Inc. was founded in 2010 and is based in Estero, Florida. [Read more]
Full Company ProfileFinancial Performance
Financial StatementsNews
Exousia Pro, Inc. Announces Executed LOI for Strategic Acquisition of High-Revenue Telehealth Platform to Accelerate Nutraceutical Commercialization
ORLANDO, FL / ACCESS Newswire / December 11, 2025 / Exousia Pro, Inc. (OTCID:MAJI), a clinical-stage biotechnology company focused on proprietary exosome-based delivery systems, is excited to announce...
Exousia Pro, Inc. Revolutionizes Nutraceuticals With Launch Of Maxasome(TM): The First All-Natural, Biologically Active Exosomal Supplement
ORLANDO, FLORIDA / ACCESS Newswire / December 5, 2025 / Exousia Pro, Inc. (OTCID:MAJI), a clinical-stage biotechnology company leveraging proprietary exosome-based delivery systems, today announced th...
Exousia Pro, Inc. Completes Exclusive Licensing Agreement With the University of Central Florida for Novel Cancer Diagnostic and Therapy Platforms
ORLANDO, FLORIDA / ACCESS Newswire / December 2, 2025 / Exousia Pro, Inc. (OTCID:MAJI), a clinical-stage biotechnology company focused on advanced exosome-based delivery systems, today announced the e...
Exousia Pro Initiates Strategic Realignment, Acquires Controlling Stake in SEC-Reporter Lamy (LMMY) in All-stock Exchange Transaction for Exousia AI, to Advance Growth and Enhance Shareholder Value
ORLANDO, FLORIDA / ACCESS Newswire / November 17, 2025 / Exousia Pro, Inc. (OTCID:MAJI), a clinical-stage biotechnology company focused on advanced exosome-based delivery systems, today announced it h...
Exousia Pro Announces Breakthrough In Exosome-Based Delivery
Successful loading of CBD material accelerates the path to revenue. ORLANDO, FL / ACCESS Newswire / November 4, 2025 / Exousia Pro, Inc. (OTCPINK:MAJI), a clinical-stage biotechnology company focused ...
Exousia Pro is Excited to Announce that it has Received Orphan Drug Designation from the FDA
Exousia Pro is in a unique position, as only 11% of ODAs are awarded at the preclinical stage. ORLANDO, FLORIDA / ACCESS Newswire / October 28, 2025 / Exousia Pro, Inc. (formerly Marijuana, Inc.) (OTC...
Exousia Pro Announces Groundbreaking Study to Revolutionize the Global Edibles Market with CBD-Loaded Exosomes
ORLANDO, FLORIDA / ACCESS Newswire / September 29, 2025 / Exousia Pro, Inc. (OTCPINK:MAJI), a clinical-stage biotechnology company focused on advanced exosome-based therapies, today announced its plan...
Exousia Pro Reports Positive Outcome in Legal Proceeding
Focused on Protecting Shareholder Value and Advancing Core Business ORLANDO, FLORIDA / ACCESS Newswire / September 26, 2025 / Exousia Pro, Inc. (OTCPINK:MAJI), a clinical-stage biotechnology company f...
Exousia Pro Files Provisional Patent for Novel Extracellular Vesicle Loading Method, Tapping into Multi-Billion Dollar Markets
ORLANDO, FL / ACCESS Newswire / September 10, 2025 / Exousia Pro, Inc. (OTCPINK:MAJI), a clinical-stage biotechnology company and innovator in exosome-based therapies, today announced a key strategic ...
Exousia Pro Announces Strategic Acquisition to Launch a New Telehealth Division
Exousia Health is expected to have an initial patient base of 1,000 active clients, projected to generate approximately $50,000 in monthly revenue. ORLANDO, FL / ACCESS Newswire / September 8, 2025 / ...
Exousia Pro Creates New Subdivisions
Exousia Pro aims to develop three new subdivisions and launch new products during the 4th quarter. The market for our new products is currently valued at $8.7 billion, projected to grow to $18.5 billi...
Exousia Pro Files Reg A.
ORLANDO, FLORIDA / ACCESS Newswire / June 25, 2025 / Exousia Pro, Inc. (OTCPINK:MAJI), Exousia Pro, Inc., a clinical-stage biotech company utilizing exosomes in therapies helpful in the treatment of c...
Exousia Pro Finishes Preclinical Trial for Glioblastoma Ahead of Schedule - Bolstering Orphan Drug Application
- Rigorous humanized mouse model enhances credibility and translatability of results - Key preclinical data to support FDA Orphan Drug Application - In vitro success signals potential for exosome-base...
Exousia Pro CSO Revealed Significant Findings About the Glioblastoma Study in a Spaces Interview
A published paper shows NANOG Expression was almost 100% effective at eradicating tumor cells ORLANDO, FL / ACCESS Newswire / April 21, 2025 / MARIJUANA INC. (OTC PINK:MAJI), dba Exousia Pro, Inc., a ...
Exousia Pro Offers Guidance on New Subdivisions
ORLANDO, FL / ACCESS Newswire / April 17, 2025 / MARIJUANA INC. (OTCPINK:MAJI), dba Exousia Pro, a clinical-stage biotech company utilizing exosomes in the treatment of cancer and other diseases, is p...
Exousia Pro to Deliver 500 Billion Dried Exosomes for Trade Show
Exousia Pro has a 60% margin built-in on each order of exosomes ORLANDO, FLORIDA / ACCESS Newswire / April 8, 2025 / MARIJUANA INC. (OTCPINK:MAJI), dba Exousia Pro, Inc., a clinical-stage biotech comp...
Exousia Pro Issues Update on Name Change
ORLANDO, FLORIDA / ACCESS Newswire / April 3, 2025 / MARIJUANA INC. (OTC PINK:MAJI), dba Exousia Pro, Inc., a clinical-stage biotech company utilizing exosomes in the treatment of cancer and other dis...
Exousia Pro Has Appointed Matthew Dwyer As Its New President
ORLANDO, FL / ACCESS Newswire / April 2, 2025 / MARIJUANA INC. (OTC PINK:MAJI), dba Exousia Pro, Inc., a clinical-stage biotech company using exosomes in the treatment of cancer and other maladies, is...
Exousia Pro Issues and Update on its FDA Orphan Drug Status
ORLANDO, FL / ACCESS Newswire / April 1, 2025 / MARIJUANA INC. (OTC PINK:MAJI), dba Exousia Pro, Inc., a clinical-stage biotech company using exosomes in the treatment of cancer and other maladies, is...
Exousia Pro Officially Announces the Production of Plant-Based Exosomes Has Begun
Exousia Pro will be sending out samples to clients expected to place orders ORLANDO, FL / ACCESS Newswire / March 25, 2025 / MARIJUANA INC. (OTC PINK:MAJI), dba Exousia Pro, Inc., announces the offici...
Exousia Has Successfully Renegotiated Its License Agreement
ORLANDO, FL / ACCESS Newswire / March 18, 2025 / MARIJUANA INC. (OTCPINK:MAJI), dba Exousia Pro, Inc., a clinical-stage biotech company using exosomes in the treatment of cancer and other maladies, is...